Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) in Adult Patients With Upper Limb Spasticity

NCT07242300 is registered in ClinicalTrials.gov with JHM BioPharma (Tonghua) Co. , Ltd. as lead sponsor.

NCT NCT07242300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07242300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) in Adult Patients With Upper Limb Spasticity
Lead sponsor
JHM BioPharma (Tonghua) Co. , Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
December 11, 2025
Completion date
January 31, 2028
Enrollment
207 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

upper limb spasticity (uls)